跳至主要内容
临床试验/NCT07456761
NCT07456761尚未招募不适用

Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial

South Egypt Cancer Institute0 个研究点目标入组 80 人开始时间: 2026年4月1日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
80
主要终点
Cumulative opioid consumption (IV morphine equivalents) during the first 24 postoperative hours

研究概览

简要总结

The goal of this clinical trial is to detect whether pregabalin retard (82.5 mg or 165 mg) improves analgesia after elective laparoscopic abdominal surgery in adults. It will also evaluate the safety of both doses.

The main questions it aims to answer are:

Does the higher dose (165 mg) reduce the total amount of opioids needed in the first 24 hours after surgery compared to the lower dose (82.5 mg)? Do the pain scores differ between the two doses? Are there differences in side effects between the two doses?

Researchers will compare two different doses of pregabalin retard to determine which provides better pain control with fewer side effects.

Participants will:

Take one dose of pregabalin retard (82.5 mg or 165 mg) before surgery Receive standard anesthesia and multimodal pain treatment Have their pain levels and opioid use monitored for 24 hours after surgery Be assessed for side effects such as dizziness, nausea, or sedation

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-75 years
  • ASA physical status I-III
  • Scheduled for elective laparoscopic abdominal surgery under general anesthesia (e.g. laparoscopic cholecystectomy, appendectomy, diagnostic/therapeutic laparoscopic procedures without expected conversion to open surgery)
  • Ability to understand the NRS pain scale and the study procedures
  • Written informed consent obtained

排除标准

  • Known allergy or intolerance to pregabalin, gabapentinoids, or study medications
  • Chronic opioid use (daily use >30 mg oral morphine equivalent for >2 weeks preoperatively)
  • Regular use of gabapentin or pregabalin within 30 days
  • Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or on dialysis
  • Severe hepatic impairment (Child-Pugh C)
  • Uncontrolled epilepsy or other major neurological disorder
  • Severe psychiatric disease, alcohol or substance abuse
  • Pregnancy or breastfeeding
  • Planned postoperative ICU admission for reasons other than routine overnight monitoring
  • Conversion to open abdominal surgery (these patients will be analyzed in sensitivity or excluded, predefined in analysis plan)

研究组 & 干预措施

Group I (Low dose)

Active Comparator

Participants of this Arm will take pregabalin retard 82.5 mg orally with a sip of water, 1-2 hours before induction of anesthesia.

干预措施: Pregabalin retard 82.5 mg (Drug)

Group II (High dose)

Active Comparator

Participants of this Arm will take pregabalin retard 165 mg orally with a sip of water, 1-2 hours before induct

干预措施: Pregabalin retard 165 mg (Drug)

结局指标

主要结局

Cumulative opioid consumption (IV morphine equivalents) during the first 24 postoperative hours

时间窗: 24 hours

次要结局

  • Postoperative pain intensity(2-24 hours postoperative)

研究者

发起方
South Egypt Cancer Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Muhammad Gamal Thabet Ahmed

Lecturer of anesthesia, intensive care medicine and pain therapy

South Egypt Cancer Institute

相似试验